Qualigen Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
FFR$0.89-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statement of Changes in Stockholders’ Equity (Deficit)
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)
| Series A-2 · Series A-3 · Series B · Total | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Convertible · Convertible · Convertible · Additional · Stockholders’ | |||||||||||
| Preferred Stock · Preferred Stock · Preferred Stock · Common Stock · Paid-In · Accumulated · Equity | |||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | (Deficit) | |
| Balance at December 31, 2024 | 6,256 | $5,716,400 | — | $— | — | $— | 736,431 | $65,314 | $119,958,897 | $(123,061,575) | $2,679,036 |
| Issuance of common stock for the conversion of Series A-2 preferred shares | (3,235) | (2,893,306) | — | — | — | — | 888,879 | 889 | 2,892,417 | — | — |
| Stock-based compensation | — | — | — | — | — | — | — | — | 269 | — | 269 |
| Net loss | — | — | — | — | — | — | — | — | — | (2,646,172) | (2,646,172) |
| Balance at March 31, 2025 | 3,021 | 2,823,094 | — | — | — | — | 1,625,310 | 66,203 | 122,851,583 | (125,707,745) | 33,134 |
| Issuance of common stock for the conversion of Series A-2 preferred shares | (37) | (33,087) | — | — | — | — | 10,165 | 10 | 33,076 | — | — |
| Net loss | — | — | — | — | — | — | - | — | — | (1,685,417) | (1,685,417) |
| Balance at June 30, 2025 | 2,984 | 2,790,007 | — | — | — | — | 1,635,475 | 66,213 | 122,884,659 | (127,393,162) | (1,652,283) |
| Issuance of common stock for the conversion of Series A-2 preferred shares | (2,383) | (2,130,967) | — | — | — | — | 1,023,658 | 1,024 | 2,129,945 | — | — |
| Issuance of Series A-3 preferred shares upon closing of private placement | — | — | 4,500 | 4,257,937 | — | — | — | — | — | — | 4,257,937 |
| Issuance of Series B preferred shares upon closing of private placement | — | — | — | — | 39,943 | 31,183,357 | — | — | — | — | 31,183,357 |
| Issuance of common stock and warrants upon closing of private placement | — | — | — | — | — | — | 497,689 | 497 | 6,795,387 | — | 6,795,885 |
| Net loss | — | — | — | — | — | — | — | — | — | (2,037,819) | (2,037,819) |
| Balance at September 30, 2025 | 601 | $659,040 | 4,500 | $4,257,937 | 39,943 | $31,183,357 | 3,156,822 | $67,734 | $131,809,991 | $(129,430,981) | $38,547,077 |
| Series A-2 · Series A-3 · Series B · Total | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Convertible · Convertible · Convertible · Additional · Stockholders’ | |||||||||||
| Preferred Stock · Preferred Stock · Preferred Stock · Common Stock · Paid-In · Accumulated · Equity | |||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | (Deficit) | |
| Balance at December 31, 2023 | — | $— | — | $— | — | $— | 107,243 | $43,262 | $114,655,565 | $(116,802,384) | $(2,103,557) |
| Monthly redemptions of convertible debt into common stock | — | — | — | — | — | — | 22,771 | 1,138 | 545,094 | — | 546,232 |
| Fair value of warrant modification for professional services | — | — | — | — | — | — | — | — | 9,737 | — | 9,737 |
| Stock-based compensation | — | — | — | — | — | — | — | — | 58,651 | — | 58,651 |
| Net loss | — | — | — | — | — | — | — | — | — | (2,032,751) | (2,032,751) |
| Balance at March 31, 2024 | — | — | — | — | — | — | 130,014 | 44,400 | 115,269,047 | (118,835,135) | (3,521,688) |
| Voluntary conversion of convertible debt into common stock | — | — | — | — | — | — | 28,000 | 1,400 | 278,801 | 280,201 | |
| Monthly redemptions of convertible debt into common stock | — | — | — | — | — | — | 22,726 | 1,137 | 355,959 | — | 357,096 |
| Stock issued upon partial exercise of warrants | — | — | — | — | — | — | 11,538 | 577 | 149,423 | — | 150,000 |
| Stock-based compensation | — | — | — | — | — | — | — | — | 33,086 | — | 33,086 |
| Net loss | — | — | — | — | — | — | — | — | — | (1,576,558) | (1,576,558) |
| Balance at June 30, 2024 | — | — | — | — | — | — | 192,278 | $47,514 | $116,086,316 | $(120,411,693) | $(4,277,863) |
| Issuance of common stock and prefunded warrants in public offering | — | — | — | — | — | — | 294,481 | 14,724 | 3,038,624 | — | 3,053,348 |
| Voluntary conversion of convertible debt into common stock | — | — | — | — | — | — | 38,222 | 1,911 | 452,972 | — | 454,883 |
| Fair value of warrant modification for professional services | — | — | — | — | — | — | — | — | 2,299 | — | 2,299 |
| Stock issued upon partial exercise of warrants | — | — | — | — | — | — | 20,460 | 1,023 | 264,958 | — | 265,981 |
| Restricted share settlements issued to former Board members | — | — | — | — | — | — | 2,843 | 142 | 142,209 | — | 142,351 |
| Fair value of warrants reclassified from equity to liabilities | — | — | — | — | — | — | — | — | (14,998) | — | (14,998) |
| Stock-based compensation | — | — | — | — | — | — | — | — | 27,208 | — | 27,208 |
| Net loss | — | — | — | — | — | — | — | — | - | (1,794,060) | (1,794,060) |
| Balance at September 30, 2024 | — | $— | — | $— | — | $— | 548,284 | $65,314 | $119,999,588 | $(122,205,753) | $(2,140,851) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.